Neuroone Medical Technologies (NMTC) Short term Debt (2016 - 2024)

Neuroone Medical Technologies (NMTC) reported Short term Debt of $121896.0 for Q1 2024, down 5.59% sequentially from $129116.0 in Q3 2023.

Neuroone Medical Technologies (NMTC) Short term Debt (2016 - 2024) Analysis & Trends

Neuroone Medical Technologies has disclosed Short term Debt across 6 years of filings, most recently posting $121896.0 for Q1 2024.

Quarterly Short term Debt changed N/A year-over-year to $121896.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $121896.0 (changed N/A YoY) and the FY2023 annual result came in at $129116.0, changed N/A from the prior year.
Short term Debt retreated to $121896.0 in Q1 2024, from $129116.0 in the prior quarter.
Across five years, Short term Debt topped out at $129116.0 in Q3 2023 and bottomed at $121896.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Neuroone Medical Technologies	26.73 Mn	23.93 Mn	990,264.00

Download Data